scholarly journals Exploring the divalent effect in fucosidase inhibition with stereoisomeric pyrrolidine dimers

2016 ◽  
Vol 14 (20) ◽  
pp. 4718-4727 ◽  
Author(s):  
Audrey Hottin ◽  
Daniel W. Wright ◽  
Elena Moreno-Clavijo ◽  
Antonio J. Moreno-Vargas ◽  
Gideon J. Davies ◽  
...  
Keyword(s):  
Enzyme Inhibitor ◽  
Mechanisms Of Action ◽  
Crystallographic Analysis ◽  
Enzymatic Assays ◽  
Inhibitor Complex

The possible mechanisms of action of a dimeric fucosidase inhibitor are discussed through enzymatic assays of a series of analogues and crystallographic analysis of the enzyme-inhibitor complex.

m-[o-(2-Chloro-5-Fluorosulfonylphenylureido)Phenoxybutoxy]Benzamidine: Affinity Labeling Reagent Which Can Identify Secondary Binding Sites of Coagulation Complement and Fibrinolytic Serine Proteases

1979 ◽  
Author(s):  
D Bing ◽  
D Robison ◽  
J Andrews ◽  
R Laura
Keyword(s):  
Binding Sites ◽  
Serine Proteases ◽  
Enzyme Inhibitor ◽  
Molecular Model ◽  
Factor Xa ◽  
Affinity Labeling ◽  
Catalytic Center ◽  
Inhibitor Complex ◽  
Polypeptide Chains ◽  
Kinetics Of

We have determined that m-[o-(2-chloro-5-fluorosulfonylphenylureido)phenoxybutoxy]benza-midine [mCP(PBA)-F] is an affinity labeling reagent which labels both polypeptide chains of thrombin, factor Xa, complement component CIS and plasmin. As this means it is reacting outside of the catalytic center, we have called this reagent an exo-site affinity labeling reagent. Progressive irreversible inhibition of these enzymes by this reagent is rapid (k1st 2.5-4.6 x 10-3sec-1), the kinetics of inactivation are consistent with inhibition proceding via formation of a specific enzyme-inhibitor complex analogous to a Michaelis-Menton complex (KL - 115-26 μM), and diisopropylfluorophosphate or p-amidino-phenylmethanesulfonyfluoride Prevent labeling by [3H]mCP(PBA)-F. A molecular model of mCP(PBA)-F shows that the reactive SO2F group can be 17 A from the cationic amidine. The data are consistent with the hypothesis that both peptide chains are required for the specific proteolytic activity exhibited by these proteases and that the peptide chain which does not contain the active site serine is close to the catalytic center. (Supported by NIH and AHA grants

Optimal Duration of the Preincubation Phase in Enzyme Inhibition Experiments

2020 ◽  
Author(s):  
Petr Kuzmic
Keyword(s):  
Enzyme Inhibition ◽  
Dose Response ◽  
Enzyme Inhibitor ◽  
Single Point ◽  
Association Rate ◽  
Weakly Bound ◽  
Inhibitor Complex ◽  
Dissociation Equilibrium ◽  
Optimal Duration ◽  
Algebraic Formula

This report describes an algebraic formula to calculate the optimal duration of the pre-incubation phase in enzyme-inhibition experiments, based on the assumed range of expected values for the dissociation equilibrium constant of the enzyme–inhibitor complex and for the bimolecular association rate constant. Three typical experimental scenarios are treated, namely, (1) single-point primary screening at relatively high inhibitor concentrations; (2) dose-response secondary screening of relatively weakly bound inhibitors; (3) dose-response screening of tightly-bound inhibitors.

A Very Short Hydrogen Bond Provides Only Moderate Stabilization of an Enzyme-Inhibitor Complex of Citrate Synthase

Biochemistry ◽  
1994 ◽  
Vol 33 (25) ◽  
pp. 7753-7759 ◽  
Author(s):  
Ken C. Usher ◽  
S. James Remington ◽  
David P. Martin ◽  
Dale G. Drueckhammer
Keyword(s):  
Hydrogen Bond ◽  
Citrate Synthase ◽  
Enzyme Inhibitor ◽  
Inhibitor Complex ◽  
Short Hydrogen Bond

scholarly journals Kinetic properties of the primary inhibitor of plasmin from human plasma

1977 ◽  
Vol 163 (2) ◽  
pp. 389-391 ◽  
Author(s):  
U Christensen ◽  
I Clemmensen
Keyword(s):  
Human Plasma ◽  
Enzyme Inhibitor ◽  
Kinetic Properties ◽  
Inhibitor Complex ◽  
Rapid Formation ◽  
Plasmin Inhibitor

The interaction of human plasmin with the newly discovered alpha2-plasmin inhibitor was investigated. It was found from rate measurements that the reaction involves the rapid formation of a first enzyme-inhibitor complex, followed by the slow irreversible transition to another complex. L-Lysine influences the first step, but not the second.

Enzyme-Inhibitor Complex in a Tryptophan-Requiring Mutant of Neurospora crassa

Science ◽  
1957 ◽  
Vol 126 (3282) ◽  
pp. 1068-1069 ◽  
Author(s):  
S. R. SUSKIND ◽  
L. I. KUREK
Keyword(s):  
Neurospora Crassa ◽  
Enzyme Inhibitor ◽  
Inhibitor Complex

scholarly journals Structure of Enzyme-Inhibitor Complex Determined by Neutron Crystallography

2013 ◽  
Vol 55 (1) ◽  
pp. 47-51
Author(s):  
Taro TAMADA ◽  
Motoyasu ADACHI ◽  
Kazuo KURIHARA ◽  
Ryota KUROKI
Keyword(s):  
Enzyme Inhibitor ◽  
Inhibitor Complex ◽  
Neutron Crystallography

TWO-SIDE IMMUNOASSAYS OF ENZYME-INHIBITOR COMPLEXES FOR THE DIAGNOSIS OF THROMBOPHILIC STATES

1987 ◽  
Author(s):  
H Bleyl
Keyword(s):  
Heart Surgery ◽  
Enzyme Inhibitor ◽  
Open Heart Surgery ◽  
Coagulation Cascade ◽  
Clotting Factors ◽  
Inhibitor Complex ◽  
At Iii ◽  
Complex Measurement ◽  
Sandwich Assays ◽  
Time Of Admission

The diagnosis of prethrombotic states requires methods which detect products of intravasal activation of the coagulation cascade.Two-side immunoassays for antithrombin complexes with clotting factors were developed (IXi-AT, Xi-AT, IIi- AT). These sandwich assays permit the diagnosis of hypercoagulability in the presence or absence of heparin. The biological half live time of the thrombin-antithrombin-complex was found to be about 15 min. Healthy young men 20-25 years old (n=30) have a thrombin-antithrombin-complex concentration of 0.4 ± 0.2 mU/ml thrombin equivalent (S 2238). Patients with acute myocardial infarction (n=40) showed at the time of admission to the hospital up to 10-fold (n=14), up to 100-fold (n=13) more than 100-fold (n=13) elevated thrombin-antithrombin-complex concentrations. Patients with gastrointestinal cancer showed sometime excessive elevated enzyme-inhibitor complexes.No correlation was found between thromboplastine time (Quick) and complex concentration in patients under anticoagulant therapy with dicumarole. In patients under dialysis as well as in patients under open heart surgery with extracorporal circulation, the biocompatibility can be monitored by inhibitor complex measurement.

scholarly journals Interruption of tumor-associated platelet consumption with platelet enzyme inhibitors

Blood ◽  
1982 ◽  
Vol 59 (6) ◽  
pp. 1252-1258 ◽  
Author(s):  
SJ Slichter ◽  
PL Weiden ◽  
MR O'Donnell ◽  
R Storb
Keyword(s):  
Synergistic Effect ◽  
Enzyme Inhibitors ◽  
Enzyme Inhibitor ◽  
Phosphodiesterase Inhibitor ◽  
Metastatic Tumor ◽  
Mechanisms Of Action ◽  
Cyclooxygenase Inhibitor ◽  
Normal Platelet ◽  
Naturally Occurring ◽  
Platelet Survival

Abstract Twenty dogs with naturally occurring metastatic tumors were treated with anticoagulants (Warfarin) or platelet enzyme inhibitor drugs (dipyridamole, dipyridamole plus aspirin, RA233, sulfinpyrazone, or a combination of RA233 and sulfinpyrazone) to determine if tumor-related reductions in platelet survival and concentration could be reversed. Anticoagulation was ineffective, while platelet enzyme inhibitors were able to produce improvements in platelet survival. Of the 18 dogs with metastatic tumor treated with platelet enzyme inhibitors, only 5 (28%) showed a reduction in platelet survival during the first week of observation on therapy compared to their baseline survivals. This is significantly different than the decreases in platelet survivals observed in 8 of 10 untreated dogs (80%) with metastatic tumor observed for the same interval. Furthermore, 8 of the 18 treated dogs (44%) had platelet survivals within 2 standard deviations of normal, compared to only 1 of 10 untreated dogs. Of the 8 dogs with normal platelet survivals, 6 were treated with a combination of a phosphodiesterase inhibitor (RA233 or dipyridamole) and a cyclooxygenase inhibitor (sulfinpyrazone or aspirin). The combination of RA233 and sulfinpyrazone was the best drug program tested and resulted in normal platelet survivals in 63% and improved platelet counts in 75% of the animals treated. Thus, platelet enzyme inhibitors with different mechanisms of action may have a synergistic effect in reversing the abnormal platelet hemostasis found in a variety of spontaneously occurring canine neoplasms.

Sign in / Sign up

Export Citation Format

Share Document